Should double cord blood transplants be the preferred choice when a sibling donor is unavailable? [0.03%]
兄弟捐献者不可用时，双重脐带血移植应作为首选吗？
John E Wagner
John E Wagner
Umbilical cord blood transplant is an important alternative stem cell source for both children and adults with haematologic malignancies. Umbilical cord blood units are rapidly available and have less stringent human leucocyte antigen (HLA)...
Frederick R Appelbaum
Frederick R Appelbaum
The conditioning regimen administered prior to allogeneic transplantation for acute myeloid leukaemia (AML) must be sufficiently immunosuppressive to ensure engraftment, and contributes to the anti-leukaemic impact of the procedure. A broad...
High-resolution typing for unrelated donor transplantation: how far do we go? [0.03%]
无关供者移植的高分辨率分型究竟应该达到何种程度？
Mary M Horowitz
Mary M Horowitz
For best results with unrelated donor transplantation of acute myeloid leukaemia (AML) patients, high-resolution typing should be completed for human leucocyte antigens (HLAs) A, B, C and DR. In the absence of an HLA-identical sibling, an u...
Elihu Estey
Elihu Estey
Older patients are generally, and arbitrarily, defined as those aged 60 and above. It is important to recognise that the effect of age is modulated by numerous other prognostic factors such as performance status, presence of various co-morb...
Richard M Stone
Richard M Stone
Acute myeloid leukaemia (AML) is a complicated, heterogeneous disease and the prognostic factors may be useful in deciding upon appropriate therapy. Cytogenetic testing at diagnosis yields critical prognostic information, but more refinemen...
Maria R Baer
Maria R Baer
Maintenance therapy is not part of current standard treatment for acute myeloid leukaemia (AML). However, in other leukaemias, maintenance therapy is used to prolong responses and increase the cure rate. While maintenance chemotherapy has n...
Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)? [0.03%]
强化诱导治疗在急性髓系白血病(AML)中的作用探讨
Jacob M Rowe
Jacob M Rowe
Intensifying induction is not a new concept, but some recent and emerging information suggests that intensifying induction may be a relevant strategy for both young and older patients with acute myeloid leukaemia (AML). There are several po...
Steven Grant
Steven Grant
The heterogeneity of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has led to a multiplicity of treatments, from cytotoxic agents to signal transduction modulators, cell-cycle inhibitors and epigenetic therapies. While s...
Kenneth Kaushansky,Helen M Ranney
Kenneth Kaushansky
It has been known for sometime that thrombopoietin acts on megakaryocytic progenitor cells to stimulate platelet production. It has recently been discovered that it also stimulates the self-renewal and expansion of normal murine and human h...
Ross L Levine
Ross L Levine
In recent years, a series of studies have provided genetic insight into the pathogenesis of myeloproliferative neoplasms (MPNs). It is now known that JAK2V617F mutations are present in 90% of patients with polycythaemia vera (PV), 60% of pa...